To the Editor We read with great interest the article by Divithotawela et al,1 which demonstrated the posttransplant long-term outcomes were similar between ex vivo lung perfusion (EVLP)–treated lung transplant (LTx) and standard LTx, although the quality of donor lungs was worse with EVLP-treated LTx. To our knowledge, this study is the largest study of EVLP and includes 230 EVLP cases. We congratulate Divithotawela et al1 for this excellent study.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Tian D, Wang Y, Deng S. Should All Donors Be Treated by Ex Vivo Lung Perfusion? JAMA Surg. Published online March 25, 2020. doi:10.1001/jamasurg.2020.0043
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: